Goldstein, Rachel
Rabkin, Natalie
Buchman, Noa
Jacobs, Aviya R.
Sandouka, Khaled
Raccah, Bruria
Fisher Negev, Tamar
Matok, Ilan
Bialer, Meir http://orcid.org/0000-0003-2046-4171
Muszkat, Mordechai
Funding for this research was provided by:
Ministry of Justice IL
Hebrew University of Jerusalem
Article History
Accepted: 25 February 2024
First Online: 23 March 2024
Declarations
:
: Open access funding provided by Hebrew University of Jerusalem. This work was funded by a research grant from the Estates Committee, Israel Ministry of Justice (proposal submitted to the Chief Scientist, Ministry of Health) to Mordechai Muszkat 2021–24.
: Meir Bialer received speaker’s or consultancy fees from Clexio Bioscines, Guidepoint, Meditec (Sam-On,) Pharma Two B, Selene Therapeurics, Shackelford Pharamad, USWorldMeds, and Xenon Pharma. Mordechai Muszkat recieved honorarai from Roche and a research grant from the Pfizer Independent Galobal Medical Grant. Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R. Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, and Ilan Matok have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: RG and MM had the idea for the article. The literature search and data analysis were performed by RG, NR, NB, ARJ, KS, BR, TF, IM and MM. RG, NR, NB, ARJ, KS, BR, and TF produced an initial draft of the manuscript under guidance and supervision from IM, MB, and MM. RG, NR, MB, and MM contributed to a critical evaluation of the data and to the revision and finalization of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.